Exploring US High Growth Tech Stocks This May 2026

Over the last 7 days, the United States market has risen by 1.1% and is up 27% over the past year, with earnings forecasted to grow by 17% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to leverage these promising conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Karooooo (KARO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Karooooo Ltd. offers a mobility software-as-a-service platform for connected vehicles across various regions including South Africa, Europe, and the United States, with a market capitalization of $1.47 billion.

Operations: The company delivers a comprehensive SaaS platform for connected vehicles, serving diverse regions such as Africa, Europe, and the United States. Its business model centers on generating revenue through subscription fees from its mobility solutions.

Karooooo Ltd. is navigating a dynamic landscape with a robust strategy to enhance its subscription revenue, evidenced by its latest guidance projecting an impressive 21% EPS growth for FY 2027. Despite a dip in net income and EPS as reported in Q4 2026, annual figures show resilience with sales climbing to ZAR 5.48 billion from ZAR 4.57 billion the previous year and net income rising to ZAR 993.92 million, marking an upward trajectory from ZAR 921.03 million. This growth is complemented by a dividend increase of 20%, signaling confidence in sustained financial health and shareholder value creation.

• Navigate through the intricacies of Karooooo with our comprehensive health report here.

• Examine Karooooo's past performance report to understand how it has performed in the past.

Larimar Therapeutics (LRMR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Larimar Therapeutics, Inc. is a clinical-stage biotechnology company that develops treatments for rare diseases using its novel cell penetrating peptide technology platform, with a market cap of $404.10 million.

Operations: The company is focused on creating innovative therapies for rare diseases utilizing its proprietary cell penetrating peptide technology. With a market capitalization of approximately $404.10 million, the firm operates as a clinical-stage biotechnology entity without current revenue streams.

Larimar Therapeutics is making strides in the biotech sector, particularly with its recent breakthroughs and regulatory advancements. The company's focus on developing nomlabofusp as a potential treatment for Friedreich’s ataxia (FA) has shown promising preclinical and clinical correlations, supporting its accelerated approval pathway. Despite reporting a net loss of $29.61 million in Q1 2026, up slightly from $29.28 million the previous year, Larimar remains optimistic about its future prospects. This optimism is bolstered by the FDA granting Breakthrough Therapy Designation to nomlabofusp and aligning on using skin frataxin levels as a novel surrogate endpoint for accelerated approval. With an annual revenue growth forecast at 54.6%, Larimar is poised to outpace average market growth significantly, reflecting both innovation strength and potential market impact despite current unprofitability.

• Dive into the specifics of Larimar Therapeutics here with our thorough health report.

• Review our historical performance report to gain insights into Larimar Therapeutics''s past performance.

Cellebrite DI (CLBT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cellebrite DI Ltd. develops software and services for legally sanctioned investigations across various regions including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, with a market cap of $3.02 billion.

Operations: Cellebrite DI Ltd. focuses on providing digital intelligence solutions, primarily generating revenue through software and services tailored for legally sanctioned investigations. The company operates across multiple regions, including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.

Cellebrite DI's recent FedRAMP High Authorization for its Government Cloud platform underscores its pivotal role in enhancing federal data security, marking a significant stride in digital forensics within the tech landscape. With an annual revenue growth of 14.7% and earnings forecast to rise by 21.6% per year, the company's financial trajectory is robust, complemented by strategic leadership changes aimed at fostering innovation and technology advancement. Moreover, Cellebrite's R&D commitment is evident from its latest product releases that address complex security needs across various government sectors, positioning it as a crucial player in high-stakes data integrity and law enforcement support. This blend of technological prowess and solid financial health suggests a promising outlook for Cellebrite in the evolving tech domain.

• Take a closer look at Cellebrite DI's potential here in our health report.

• Evaluate Cellebrite DI's historical performance by accessing our past performance report.

Next Steps

• Navigate through the entire inventory of 68 US High Growth Tech and AI Stocks here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com